Hi大家
AeyeGsee为大家带来最新一期StayOnTop，知道的就复习一下，不知道的赶紧知道一下，都是吹牛的料。
医疗先见
Medical Pulse
GE医疗推出新型AI床旁超声系统
GE Healthcare Launches New AI Bedside Ultrasound System
GE医疗最新发布Venue Sprint床旁超声系统，集成AI技术，提升便携性和图像质量。该系统以平板电脑形式提供，适用于重症护理、急救药物、医疗运输等多种环境。新系统简化了学习过程，配备了高级临床工具和最新ViewPoint 6版本，旨在提高工作效率。此外，Venue Sprint还具备膀胱体积工具、自动体积工具等辅助功能，以支持不同经验水平的临床医生进行患者检查。
GE Healthcare has just released the Venue Sprint bedside ultrasound system, which integrates AI technology to enhance portability and image quality. The system is provided in the form of a tablet and is suitable for various environments such as critical care, emergency medicine, and medical transportation. The new system simplifies the learning process and is equipped with advanced clinical tools and the latest ViewPoint 6 version, aiming to improve work efficiency. In addition, Venue Sprint also has auxiliary functions such as bladder volume tool, automatic volume tool, etc., to support clinical doctors of different experience levels for patient examination.
发布日期：2024年09月20日
蔡司光学与星创视界联合发布滑雪视觉新体验
Zeiss and NOVA VISION Jointly Release New Skiing Visual Experience
蔡司光学与星创视界于9月21日在北京顺迈总店举办滑雪视觉新体验发布会，双方宣布将在运动视觉领域展开深度合作。蔡司光学中国区营销总经理杨晓光先生表示，新推出的蔡司滑雪镜将高端科技融入滑雪运动，提供清晰、安全的视觉体验。星创视界集团董事长王智民先生强调，NSVE运动视觉优化将为消费者提供个性化服务，提升运动视觉体验。蔡司滑雪镜采用SONAR技术，提升色彩感知和地势判断能力，满足滑雪爱好者需求。
Zeiss and NOVA VISION held a new skiing visual experience release conference at the Beijing Shunmai General Store on September 21, announcing that they will carry out in-depth cooperation in the field of sports vision. Mr. Yang Xiaoguang, General Manager of Marketing of Zeiss China, said that the newly launched Zeiss ski goggles will integrate high-end technology into skiing, providing a clear and safe visual experience. Mr. Wang Zhimin, Chairman of NOVA VISION Group, emphasized that NSVE sports vision optimization will provide personalized services for consumers and enhance sports visual experience. Zeiss ski goggles use SONAR technology to enhance color perception and terrain judgment ability, meeting the needs of skiing enthusiasts.
发布日期：2024年09月21日
GE医疗获得FDA批准用于阿尔茨海默氏症诊断的脑成像产品
GE Healthcare Receives FDA Approval for Brain Imaging Product for Alzheimer’s Diagnosis
GE医疗宣布，美国食品药品监督管理局（FDA）已批准其新型脑成像工具，用于评估潜在的阿尔茨海默氏症患者。该工具结合了正电子发射断层扫描（PET）技术，通过MIMneuro软件提供的Centiloid scale工具，辅助临床医生更准确地评估患者大脑中的淀粉样斑块密度。这一进展对于阿尔茨海默氏症的诊断和治疗具有重要意义。
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved its new brain imaging tool for assessing potential Alzheimer’s disease patients. The tool combines positron emission tomography (PET) technology and assists clinical doctors in more accurately assessing the density of amyloid plaques in the patient’s brain through the Centiloid scale tool provided by MIMneuro software. This progress is of great significance for the diagnosis and treatment of Alzheimer’s disease.
发布日期：2024-09-22
安斯泰来佐妥昔单抗获欧盟批准
Astellas’ zolbetuximab Approved by EU
安斯泰来制药集团宣布，其佐妥昔单抗（VYLOY）获得欧盟批准，与化疗联合用于治疗晚期胃或胃食管交界处腺癌。该药物基于改善患者生存结果的考虑，被建议维持孤儿药的认定。
Astellas Group announced that its zolbetuximab (VYLOY) has been approved by the EU for use in combination with chemotherapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma. The drug is recommended to maintain orphan drug status based on improving patient survival outcomes.
发布日期：2024年09月26日
康哲药业新药上市许可申请获受理
CMS’s New Drug Marketing Authorization Application Accepted
康哲药业控股有限公司宣布，其磷酸芦可替尼乳膏（白癜风适应症）新药上市许可申请已获中国国家药品监督管理局受理。该药物在中国真实世界研究中取得积极结果，不良反应大部分为1级或2级。
CMS announced that its new drug marketing authorization application for Opzelura has been accepted by theChina National Medical Products Administration. The drug has achieved positive results in real-world studies in China, and most adverse reactions are grade 1 or 2.
发布日期：2024年09月26日
海和药物紫杉醇口服溶液获批上市
Haihe Biopharma’s Liporaxel Approved for Marketing
上海海和药物研究开发股份有限公司与韩国大化制药公司合作开发的紫杉醇口服溶液（研发代号：RMX3001）获得获得国家药品监督管理局药品审评中心（CDE）批准在中国大陆上市，用于治疗晚期胃癌患者。
Shanghai Haihe Biopharma Research and Development Co., Ltd. and South Korea’s DAEHWA Pharmaceutical Company have jointly developed RMX3001, which has been approved by the CDE for marketing in China for the treatment of advanced gastric cancer patients.
发布日期：2024年09月26日
Release Date: September 26, 2024
商业动向
Business Movements
博士伦：隐形眼镜巨头或面临出售，业绩与债务双重挑战
Bausch + Lomb: Contact Lens Giant May Face Sale, Dual Challenges of Performance and Debt
全球隐形眼镜行业巨头博士伦近期传出可能出售的消息，此举旨在结束与母公司博士康的分拆纷争。博士伦正与高盛合作，评估市场反应，潜在买家可能包括私募股权集团。博士伦曾于2016年传出出售消息，但未成行。2024年业绩显示，公司收入增长但亏损扩大。母公司博士康面临210亿美元债务，其中100亿美元将在2027年底前到期。博士伦的全面分离是博士康的战略重点。若出售成功，博士康可能获得123.2亿美元至158亿美元的收益。
Bausch + Lomb, a global contact lens industry giant, has recently been rumored to be up for sale, aiming to end the spin-off dispute with its parent company, Ocuvite. Bausch + Lomb is working with Goldman Sachs to assess market reactions, with potential buyers possibly including private equity groups. Bausch + Lomb had previously been up for sale in 2016, but it did not go through. The company’s 2024 performance shows increased revenue but expanding losses. The parent company, Ocuvite, faces $21 billion in debt, with $10 billion due by the end of 2027. The complete separation of Bausch + Lomb is a strategic focus for Ocuvite. If the sale is successful, Ocuvite could gain between $12.32 billion and $15.8 billion in proceeds.
发布日期：2024年09月26日
强生公司关闭心血管和代谢药物部门
Johnson & Johnson Closes Cardiovascular and Metabolic Drug Division
强生公司宣布关闭其心血管和代谢药物部门，以适应快速变化的外部环境并发展业务。该决定主要影响销售、营销和医学事务团队。强生已将研发重点缩小至肿瘤学、免疫学和神经科学三个领域。核心产品拜瑞妥受美国《通货膨胀削减法案》影响，价格降低62%。
Johnson & Johnson has announced the closure of its cardiovascular and metabolic drug division to adapt to the rapidly changing external environment and to grow the business. The decision primarily affects the sales, marketing, and medical affairs teams. Johnson & Johnson has narrowed its R&D focus to three areas: oncology, immunology, and neuroscience. The core product Xarelto was affected by the U.S. Inflation Reduction Act, with its price reduced by 62%.
发布日期：2024年09月26日
Meta与Essilor Luxottica延长合作至2030年
Meta and Essilor Luxottica Extend Cooperation until 2030
Meta公司与Essilor Luxottica宣布将双方的智能眼镜产品合作延长至2030年，计划推出更多雷朋品牌智能眼镜。自2019年合作以来，双方已推出两代产品，新一代眼镜支持AI物体识别功能。Essilor Luxottica CEO Francesco Milleri表示，合作是眼镜成为互联世界重要工具的里程碑。Meta CEO马克·扎克伯格期待双方合作将眼镜转变为科技平台。
Meta and Essilor Luxottica have announced the extension of their smart eyewear product collaboration until 2030, with plans to launch more Ray-Ban branded smart glasses. Since the partnership began in 2019, the two sides have released two generations of products, with the new generation of glasses supporting AI object recognition capabilities. Essilor Luxottica CEO Francesco Milleri stated that the collaboration is a milestone for glasses to become an essential tool in the connected world. Meta CEO Mark Zuckerberg looks forward to the partnership transforming glasses into a technological platform.
发布日期：2024年09月23日
稳健医疗：成功收购GRI公司，打造全球医疗耗材新标杆
Winner Medical: Successfully Acquires GRI Company, Setting a New Global Benchmark for Medical Consumables
稳健医疗宣布以1.2亿美元成功收购Global Resources International, Inc.（GRI）75.2%股权，交易对价约8.4亿元人民币。此次收购标志着稳健医疗在全球化战略上迈出重要一步，通过并购加强了其在医疗耗材领域的全球竞争力。GRI公司作为全球性医疗耗材和工业防护企业，拥有强大的研发能力和生产基地，其产品线涵盖手术包、洞巾、铺单等。稳健医疗将利用GRI的技术和市场优势，提升自身在全球医疗耗材市场的竞争力。
Winner Medical announced the successful acquisition of 75.2% of the equity of Global Resources International, Inc. (GRI) for $120 million, with a transaction value of approximately 840 million yuan. This acquisition marks an important step for Winner Medical in its globalization strategy, strengthening its global competitiveness in the field of medical consumables through mergers and acquisitions. GRI, as a global medical consumables and industrial protection company, has strong R&D capabilities and production bases, with its product line covering surgical packs, drapes, and sheets. Winner Medical will leverage GRI’s technology and market advantages to enhance its competitiveness in the global medical consumables market.
发布日期：2024年09月25日
百时美施贵宝在新泽西州继续裁员
Bristol Myers Squibb Continues Layoffs in New Jersey
百时美施贵宝（Bristol Myers Squibb）在新泽西州劳伦斯维尔的裁员行动仍在继续，预计到2025年将有1134名员工受影响。此次裁员涉及79名员工，将于今年12月至明年5月间离职。此举是公司为到2025年节省约15亿美元成本而实施的“战略生产力计划”的一部分。BMS计划将节省下来的资金用于研发创新项目，以推动公司的长期增长。
Bristol Myers Squibb’s layoffs in Lawrenceville, New Jersey, are continuing, with 1,134 employees expected to be affected by 2025. This round of layoffs involves 79 employees who will depart between December of this year and May of next year. This move is part of the company’s “Strategic Productivity Plan” to save about $1.5 billion in costs by 2025. BMS plans to use the saved funds for research and development of innovative projects to drive the company’s long-term growth.
发布日期：2024年09月26日
欧健在沙巴州亚庇开设先进医疗中心
European Wellness Opens Advanced Medical Center in Kota Kinabalu, Sabah
全球再生医学和综合医疗领域的领导者欧健（European Wellness）在马来西亚沙巴州亚庇开设了其最新的EW欧健诊治中心。该中心将提供超过60项再生医学和整体健康疗法，配备尖端技术和300多名专业人员。这是公司在亚庇工业园区设立生物制药制造工厂，投资额高达8000万美元的更大扩展计划的一部分。
European Wellness, a global leader in regenerative medicine and integrated healthcare, has opened its latest EW European Wellness Treatment Center in Kota Kinabalu, Sabah, Malaysia. The center will offer over 60 regenerative medicine and holistic health therapies, equipped with cutting-edge technology and more than 300 professionals. This is part of the company’s larger expansion plan to establish a biopharmaceutical manufacturing facility in the Kota Kinabalu Industrial Park, with an investment of up to $80 million.
发布日期：2024年09月26日
蓝鸟生物公司裁员25%以降低运营成本
Bluebird Bio Inc. Lays Off 25% of Workforce to Reduce Operating Costs
蓝鸟生物公司宣布裁员约25%，主要涉及研发部门，以减少20%的现金运营费用。该重组计划预计将在明年第一季度完成。
Bluebird Bio Inc. has announced a workforce reduction of approximately 25%, primarily affecting the research and development department, in an effort to reduce cash operating expenses by 20%. The restructuring plan is expected to be completed by the first quarter of next year.
发布日期：2024年09月25日
Neuralink公司脑机接口技术获FDA认证
Neuralink’s Brain-Computer Interface Technology Receives FDA Approval
埃隆·马斯克旗下Neuralink公司宣布，其脑机接口设备“Blindsight”获得FDA突破性医疗器械认证。该技术旨在帮助失明者恢复视觉，甚至可能使天生失明者首次看到世界。脑机接口在医疗领域的应用前景广阔，预计到2040年市场规模将超过1450亿美元。中国在该领域也取得显著进展，清华大学等机构已成功进行相关临床试验。尽管存在伦理和安全风险，但政策支持和财政投入正推动该技术快速发展。
Elon Musk’s Neuralink has announced that its brain-computer interface device “Blindsight” has received breakthrough device designation from the FDA. The technology aims to help the blind regain their vision and may even allow those who have been blind from birth to see the world for the first time. The application prospects of brain-computer interfaces in the medical field are broad, with the market size expected to exceed $145 billion by 2040. China has also made significant progress in this field, with institutions such as Tsinghua University successfully conducting related clinical trials. Despite ethical and safety risks, policy support and financial investment are driving the rapid development of this technology.
发布日期：2024年09月25日
GE医疗: GE医疗与四川省经济合作局探讨合作
GE Healthcare: Discussing Cooperation with Sichuan Provincial Economic Cooperation Bureau
GE医疗（中国）有限公司董事、总经理徐俊拜访四川省经济合作局，与局长李江就加强核医疗装备和核素药物领域合作进行了深入交流。李江强调了四川医药健康产业的优势，并鼓励GE医疗在四川发展。徐俊对省经济合作局的支持表示感谢，并表达了与四川深度合作的意愿。
GE Healthcare’s (China) Co., Ltd., Director, and General Manager Xu Jun visited the Sichuan Provincial Economic Cooperation Bureau and had an in-depth exchange with Director Li Jiang on strengthening cooperation in the field of nuclear medical equipment and radio pharmaceuticals. Li Jiang emphasised the advantages of Sichuan’s pharmaceutical and health industry and encouraged GE Healthcare to develop in Sichuan. Xu Jun expressed gratitude for the support of the Provincial Economic Cooperation Bureau and conveyed his intention to deeply cooperate with Sichuan.
发布日期: 2024-09-26
强生全视助力广西学校眼健康项目
Johnson & Johnson Assists Guangxi School Eye Health Project
强生全视支持的”广西学校眼健康项目”在岑溪市马路镇中心小学开展免费视力筛查，提升学生眼健康意识。项目自2022年启动，旨在降低儿童视力损伤，促进医疗与教育资源融合，加强多部门合作。项目覆盖60所学校，为8.4万名学生提供视力筛查，培训医护人员和教师，提升基层眼科服务能力。
Johnson & Johnson’s “Guangxi School Eye Health Project” is conducting free vision screenings at the Ma Lu Town Central Primary School in Cenxi City to raise awareness of eye health among students. The project, which started in 2022, aims to reduce vision damage in children, promote the integration of medical and educational resources, and strengthen cooperation among multiple departments. The project covers 60 schools, providing vision screenings for 84,000 students, training medical staff and teachers, and enhancing the capacity of primary-level ophthalmic services.
发布日期：2024年09月20日
爱至瞳医疗科技：国产新型双眼波前验光仪获批上市
AIFOCUS Medical Technology: Domestic New Type of Binocular Wavefront Refractometer Approved for Marketing
浙江爱至瞳医疗科技有限公司宣布，其创新产品“BWFOM 主客一体双眼波前验光仪”已获得国家药监局批准的NMPA二类医疗器械注册证。该产品为浙江省眼科视光检查领域的首个创新医疗器械，填补了国内相关领域的空白。该验光仪实现了主客观一体化精准验光，颠覆了传统验光模式，为眼科视光检查带来革新。
Zhejiang AIFOCUS Medical Technology Co., Ltd. announced that its innovative product “BWFOM Integrated Binocular Wavefront Refractometer” has obtained the NMPA Class II medical device registration certificate approved by the China National Medical Products Administration. This product is the first innovative medical device in the field of ophthalmic optometry inspection in Zhejiang Province, filling the gap in the domestic related fields. The refractometer achieves integrated subjective and objective precise refraction, subverting the traditional refraction model and bringing innovation to ophthalmic optometry inspection.
发布日期：2024年09月25日
行业趋势
Industry Trends
柳州市首例Vivity Toric人工晶体植入手术圆满成功
Liuzhou’s First Vivity Toric Intraocular Lens Implantation Surgery a Complete Success
柳州市工人医院医疗集团眼科医院近日成功实施了柳州市首例Vivity Toric人工晶体植入手术，标志着医院在屈光白内障手术领域取得新进展。手术由眼外伤与白内障病区主任韦玉玲亲自操刀，为患者乔先生解决了白内障、近视、散光及老花问题，术后视力显著提升，患者满意度高。此次手术的成功，不仅为患者提供了更多治疗选择，也展示了医院眼科在技术创新和个性化治疗方面的专业能力。
Recently, the Ophthalmic Hospital of Liuzhou Workers’ Hospital Medical Group successfully performed the first Vivity Toric intraocular lens implantation surgery in Liuzhou, marking a new advancement in the field of refractive cataract surgery for the hospital. The surgery was personally conducted by Wei Yuling, the director of the Ophthalmic Trauma and Cataract Department, who resolved Mr. Qiao’s cataract, myopia, astigmatism, and presbyopia. His postoperative vision has significantly improved, and the patient is highly satisfied. The success of this surgery not only provides more treatment options for patients but also demonstrates the hospital’s professional capabilities in technological innovation and personalized treatment in ophthalmology.
发布日期：2024年09月19日
爱尔康亮相CCOS，展示屈光白内障治疗新进展
Alcon Showcases New Advances in Refractive Cataract Treatment at CCOS
爱尔康眼科学苑在2024年09月20日的CCOS大会上展示了屈光白内障治疗领域的最新进展。该机构通过一系列创新技术与治疗方案，为患者带来更精准的视力恢复。其展示的亮点包括先进的手术设备、优化的治疗方案以及个性化的术后护理，旨在提升患者的生活质量。
Alcon Ophthalmology Academy showcased the latest advancements in the field of refractive cataract treatment at the CCOS conference on September 20, 2024. The organization has brought more precise vision recovery to patients through a series of innovative technologies and treatment plans. The highlights of the exhibition included advanced surgical equipment, optimized treatment plans, and personalized postoperative care, all aimed at improving patients’ quality of life.
发布日期：2024年09月20日
北京市医保局宣布人工心脏纳入医保报销范围
Beijing Medical Insurance Bureau Announces Inclusion of Artificial Heart Implant Surgery in Medical Insurance Reimbursement Scope
北京市医保局近日宣布，将人工心脏植入手术纳入医保甲类报销范围，此举将显著减轻患者经济负担，并推动产业发展。目前，北京安贞医院、中国医学科学院阜外医院、北京朝阳医院、北京大学第三医院等四家医院已可提供医保报销的人工心脏移植手术。
The Beijing Medical Insurance Bureau recently announced that the implantation of artificial hearts will be included in the Category A reimbursement scope of medical insurance, which will significantly reduce the economic burden on patients and promote industrial development. Currently, four hospitals, including Beijing Anzhen Hospital, Fuwai Hospital of the Chinese Academy of Medical Sciences, Beijing Chaoyang Hospital, and Peking University Third Hospital, have been providing artificial heart transplant surgeries that are reimbursable by medical insurance.
发布日期：2024年09月26日
蚂蚁集团收购好大夫在线交易细节披露
Ant Group Discloses Transaction Details of the Acquisition of Haodf Online
蚂蚁集团与好大夫在线的并购交易尚未最终完成，交易价格约为2亿美金。尽管工商变更已完成，但后续流程仍存在变数。此次交易对互联网医疗行业具有重要启示，可能预示着行业新一轮并购浪潮的开始。
The acquisition of Haodf Online by Ant Group has not been finalized yet, with a transaction price of about 200 million USD. Although the industrial and commercial changes have been completed, there are still variables in the subsequent processes. This transaction is an important revelation for the online medical industry and may herald the beginning of a new round of mergers and acquisitions in the industry.
发布日期：2024年09月26日
IMC全球近视防控高峰论坛在长沙召开
The IMC Global Myopia Prevention Summit was held in Changsha
近视防控高峰论坛在中国长沙盛大召开，会议聚集了全球31位专家学者，共同探讨近视防控的全球性挑战与策略。中国在近视防控方面的国家战略和实践，如《综合防控儿童青少年近视实施方案》等政策，为全球提供了宝贵经验。此外，爱尔眼科医院集团在近视防控领域的创新举措和科研成果，为全球近视防控贡献了中国力量。
The Myopia Prevention Summit was grandly held in Changsha, China, where 31 global experts and scholars gathered to discuss the global challenges and strategies of myopia prevention and control. China’s national strategies and practices in myopia prevention, such as the “Comprehensive Prevention and Control Plan for Children and Adolescents Myopia,” have provided valuable experience for the world. In addition, the innovative measures and scientific research achievements of the Aier Eye Hospital Group in the field of myopia prevention have contributed Chinese strength to the global myopia prevention efforts.
发布日期：2024年09月25日
人事更迭
C-SuiteTransitions
智飞生物：蒋凌峰接任总裁
Zhifei Biological: Jiang Lingfeng Succeeds as President
重庆智飞生物制品股份有限公司宣布，经董事会审议通过，蒋凌峰被正式任命为公司总裁。蒋凌峰为公司创始人蒋仁生之子，此前担任副董事长及副总裁。智飞生物是一家涵盖疫苗和生物制品研发、生产、销售的国际化企业，2023年营收达529亿元。
Chongqing Zhifei Biological Products Co., Ltd. announced that, following the board of directors’ approval, Jiang Lingfeng has been officially appointed as the company’s President. Jiang Lingfeng is the son of the company’s founder Jiang Rensheng and previously served as Vice Chairman and Vice President. Zhifei Biological is an international company that covers the research and development, production, and sales of vaccines and biological products, with a revenue of 52.9 billion yuan in 2023.
发布日期：2024年09月25日
诺为泰任命亚太地区新执行总裁
Novotech Appoints New ExecutivePresident for Asia-Pacific Region
国际性合同研究组织诺为泰（Novotech）宣布任命Yooni Kim博士为亚太地区执行总裁，该任命自2024年9月1日起生效。Yooni Kim自2016年加入诺为泰，曾担任执行董事和全球临床服务副总裁。
International contract research organization Novotech announced the appointment of Dr. Yooni Kim as the Executive President for the Asia-Pacific region, effective from September 1, 2024. Dr. Yooni Kim joined Novotech in 2016 and has served as Executive Director and Vice President of Global Clinical Services.
发布日期：2024年09月26日
赛诺菲任命新首席科学家
Sanofi Appoints New Chief Scientific Officer
法国制药巨头赛诺菲（Sanofi）宣布，任命前吉利德和百时美施贵宝高管Mike Quigley为公司首席科学家，并担任全球研发部门负责人。Quigley将领导赛诺菲的全球研发团队，推动公司在多个关键治疗领域的研发工作。
French pharmaceutical giant Sanofi announced the appointment of former Gilead and Bristol-Myers Squibb executive Mike Quigley as the company’s Chief Scientific Officer and head of Global Research and Development. Quigley will lead Sanofi’s global R&D team to advance the company’s research and development efforts in several key therapeutic areas.
发布日期：2024年09月26日
葛兰素史克中国疫苗业务新负责人上任
New Head of GSK China’s Vaccine Business Takes Office
葛兰素史克中国宣布，李卫东将担任公司疫苗业务负责人，自2024年9月25日起生效。李卫东此前在威斯克生物担任副总经理兼运营负责人，拥有超过25年的医药行业经验，其中在疫苗领域超过14年。他曾在西安杨森、赛诺菲巴斯德、辉瑞等跨国药企担任要职 。
GSK China announced that Li Weidong will serve as the head of the company’s vaccine business, effective from September 25, 2024. Li Weidong was previously the deputy general manager and head of operations at WESTVAC Bio, with over 25 years of experience in the pharmaceutical industry, more than 14 of which were in the vaccine field. He has held key positions at multinational pharmaceutical companies such as Xi’an Janssen, Sanofi Pasteur, and Pfizer .
发布日期：2024年09月26日
美敦力：Jorie Soskin 担任新任副总裁兼 TAVR 和先天性心脏业务总经理
Medtronic: Jorie Soskin Takes Up Role as New Vice President and General Manager of TAVR and Congenital Heart Businesses
美敦力公司于2024年9月20日宣布了一项重要的高管变动，Jorie Soskin 被任命为公司新任副总裁兼 TAVR 和先天性心脏业务总经理。Soskin 拥有超过15年的心血管领域经验，并在美敦力收购 CoreValve 后加入公司，曾担任多个关键职务。此次任命由高级副总裁 Nina Goodheart 在 LinkedIn 上宣布，Soskin 的加入预计将为美敦力带来新的活力。尽管近期有多名高管离职，美敦力依旧在医疗器械领域保持领先地位，2023年收入达312.27亿美元 。
Medtronic announced a significant executive change on September 20, 2024, appointing Jorie Soskin as the new Vice President and General Manager of its TAVR and Congenital Heart businesses. Soskin has over 15 years of experience in the cardiovascular field and joined the company after Medtronic’s acquisition of CoreValve, where he has held several key positions. The appointment was announced by Senior Vice President Nina Goodheart on LinkedIn, and Soskin’s arrival is expected to bring new vitality to Medtronic. Despite several recent executive departures, Medtronic remains a leader in the medical device field, with revenues of $31.227 billion in 2023.
发布日期：2024年09月24日
石药创新制药：董事长潘卫东及董事杨栋因工作变动辞职
CSPC Innovation Pharmaceuticals: Chairman Pan Weidong and Director Yang Dong Resign Due to Job Changes
石药创新制药股份有限公司近期宣布，董事长潘卫东和董事杨栋因工作变动辞职。潘卫东原定任期至2026年4月6日，此次辞职后不再担任公司任何职务。杨栋同样因工作变动辞去所有职务。公司表示，二人的工作已顺利交接，不会影响公司运营。新任董事长为原总经理姚兵，其他职务也已确定接任者。石药创新制药成立于2006年，主营功能性原料、保健食品等，去年增资进入生物制药领域。
CSPC Innovation Pharmaceuticals Co., Ltd. recently announced that Chairman Pan Weidong and Director Yang Dong have resigned due to job changes. Pan Weidong’s original term was until April 6,2026, and he will not hold any position in the company after this resignation. Yang Dong also resigned from all positions due to job changes. The company stated that the two’s work has been smoothly handed over and will not affect the company’s operations. The new chairman is the former general manager Yao Bing, and successors for other positions have also been determined. CSPC Innovation Pharmaceuticals, established in 2006, mainly engages in functional materials, health food, etc., and entered the biopharmaceutical field after increasing its capital last year.
发布日期：2024年09月24日
编者按：
本期报道中，我们涵盖了从企业接班到眼科领域的最新进展，从监管机构的积极举措到光学领域的创新尝试。我们共同关注了儿童过敏性结膜炎治疗的新突破，探讨了GE医疗在AI超声系统领域的创新成果，同时，我们也对博士伦潜在的出售动向以及强生全视在广西学校眼健康项目上的积极贡献给予了关注。在高层人事变动方面，我们记录了包括诺为泰、赛诺菲、智飞生物在内的多家企业的重要调整，这些变动预示着行业未来的发展方向。
希望本期的报道能够为您提供有价值的信息。感谢您对AeyeGsee的关注与支持，我们期待在下一期与您再次相会。
免责申明：
本文章中的信息、图片均取材于网络，仅供一般参考之用，不可直接作为决策内容，AeyeGsee不对任何主体因使用本文内容而导致的任何损失承担责任。
本公众号发布的所有信息均仅供参考，不构成任何法律或其他专业建议或意见。
凡本公众号发布信息涉及知识产权等问题，请联系AeyeGsee，我们将第一时间积极配合处理相关问题。
欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载请联络AeyeGsee。
Copyright © 2024 AeyeGsee. All Rights Reserved.